Financials
Financial year 2025
Worth noting
- Figures corrected afterwards (2022).
Revenue
€ 26.8 million
▲ 1% vs 2024
Profit
Healthy€ 3.8 million
▼ 13% vs 2024
Debts
Low€ 7.4 million
▼ 18% vs 2024
PHARMA TECHNOLOGY from Nivelles, company number BE0443803803, closed financial year 2025 with a result of € 3.8 million after tax. For that financial year PHARMA TECHNOLOGY recorded revenue of € 26.8 million and equity of € 16.3 million. Compared with financial year 2024, the result moved from € 4.3 million to € 3.8 million. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on March 27, 2026.
What happened at PHARMA TECHNOLOGY?
What happened at PHARMA TECHNOLOGY in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Pharma Flex SA stepped down as director. NBB
- Claire Becker stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 3.8 million (▼ 13% vs 2024). Source: NBB ↗
- Pharma Flex SA became a director. NBB
- Claire Becker became a director. NBB
- New establishment in Nivelles. KBO
- Start of the company according to the CBE. KBO
In short
From € 3.7 million profit in 2021 to € 3.8 million profit in 2025.
Paid € 2.2 million in corporate taxes since 2021.
Best year ever: 2024, with € 4.3 million profit.
Paid out € 20.7 million in dividends to the owners in total.
A new publication or filing at PHARMA TECHNOLOGY? We notify you, reason included.
Follow PHARMA TECHNOLOGYNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
The shares are held by Pharma Flex S.A. (100%) and Martial Dollinger (0%).
Directors
According to the 2025 annual accounts
Managing director · represented by Dollinger Martial
since 2022 · until 2028
since 2022 · until 2028
Shareholders
100%
Martial Dollinger
0%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue Graham Bell 8
1402 Nivelles
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.
DOLFINANCE
€ 116,272 gross margin · 2025
PHARMA VAT UNIT
DOLLIMMO BELGIUM same network
€ -28,846 gross margin · 2025
PHARMA FLEX same network
€ 2.1 million revenue · 2025
NextGen Invest same network
€ 123,127 gross margin · 2025
+1 more
Details
- Company number
- 0443.803.803
- VAT number
- BE 0443.803.803
- Registered office
- Rue Graham Bell 8, 1402 Nivelles
- Names & denominations
- PHARMA TECHNOLOGY
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 29 March 1991
- Peppol
- Active · Active since 27 Mar 2026
- Activities · NACE
Vervaardiging van andere machines voor specifieke doeleinden neg
Vervaardiging van drukkerijmachines
Overige industrie, neg
Overige industrie, n.e.g.